Skip to content
Open access

STN-DBS exerts neuroprotection and anti-inflammatory effects in a Parkinson’s disease rat model

Aug 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 41 references
Medicine

TL;DR

A homemade device is used to investigate the effect of STN-DBS on neuroprotection and chronic neuroinflammation in a unilateral 6-hydroxydopamine (6-OHDA)-induced PD rat model and highlights that it is capable of inhibiting NF-κB, modulating glial phenotypes, mitigating neuro inflammation, and ultimately ameliorating parkinsonism deficits.

Abstract

Background Parkinson’s disease (PD) is a progressive neurodegeneration disease characterized by dopaminergic (DA) neuron loss, with chronic neuroinflammation. Subthalamic nucleus deep brain stimulation (STN-DBS) is clinically effective for the relief of parkinsonism motor symptoms. Here, we used a homemade device to investigate the effect of STN-DBS on neuroprotection and chronic neuroinflammation in a unilateral 6-hydroxydopamine (6-OHDA)-induced PD rat model. Method Male Sprague–Dawley rats received 6-OHDA injections into the striatum, followed by ipsilateral STN electrode implantation and high-frequency stimulation. Motor function was assessed by open-field and apomorphine-induced rotation tests. DA neuron survival, glial phenotype changes, and nuclear factor (NF)-κB pathway activity in the nigrostriatal system were evaluated using Western blotting, immunofluorescence, and RT-qPCR. Results STN-DBS improved motor deficits and decreased the loss of tyrosine hydroxylase-positive neurons. It promoted astrocytes presented a neuroprotective phenotype and increased expression of brain-derived neurotrophic factor, and microglia mainly presented an anti-inflammatory M2 phenotype instead of a pro-inflammatory M1 phenotype. These effects may be associated with IκB-α stabilization, the suppression of NF-κB hyperactivation, and the consequent reduction in the release of downstream pro-inflammatory cytokines. Conclusion Our findings highlight that our homemade device for STN-DBS is capable of inhibiting NF-κB, modulating glial phenotypes, mitigating neuroinflammation, and ultimately ameliorating parkinsonism deficits.

Read PDF

Similar papers

Open access Sep 2026

The 6-OHDA Model of Parkinson’s Disease: Mechanisms, Applications, and Limitations

Parkinson's disease (PD) is the second most prevalent progressive neurodegenerative disorder, in which the dopaminergic neurons are lost. Genetic and environmental factors are involved in the onset of PD. Symptoms such as tremor, balance problems, nerve pain, muscle stiffness, and mental issues are the most common. Des...

Yi-Yi Ma · 0 citations
Review Open access Sep 2026

Research Progress on the Pathogenesis of Parkinson's Disease and the Neuroregulatory Mechanism of Deep Brain Stimulation Based on Animal Models

This paper systematically reviews the experimental evidence supporting the regulatory role of deep brain stimulation at multiple levels, including the correction of abnormal neural discharges, the attenuation of pathological neural oscillations, the modulation of neurotransmitter transmission, the remodelling of synapt...

Yi-Ding Peng · 0 citations
Review Open access Aug 2026

Neuroprotective Potential of Semaglutide in Parkinson’s Disease: Mechanisms, Preclinical Evidence, and Clinical Perspectives

A narrative review evaluates the therapeutic potential of semaglutide in PD, focusing on its molecular mechanisms and preclinical and emerging clinical evidence, and suggests that semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in neuronal and glial cells, reducing microglial activation, neuro...

Dipesh Kumar, Renuka Sahu, Naveen Kumar et al. · 0 citations
Review Open access Oct 2026

Repurposing Retatrutide for Neuroprotection in Parkinson’s Disease: A Comprehensive Review

Parkinson's disease is a progressive neurodegenerative condition marked by the loss of dopaminergic neurons, mitochondrial dysfunction, oxidative stress, and persistent neuroinflammation. Recent findings suggest that impaired glucose metabolism and disrupted energy balance may play a role in the early stages of the dis...

Sivakumar G., Thilagavathi K., Narmatha K. K. et al. · 0 citations
Review Aug 2026

Nanotechnology-enabled delivery of bioactive compounds for neuroprotection in Parkinson's disease: mechanisms and future directions.

This approach aims not only to control symptoms but also to potentially control neurodegeneration in PD, and the major challenges include large-scale production, long-term safety assessment, regulatory challenges, and site-specific delivery.

P. Gaur, Prachee Raje Bisht, Sonia Lal Gupta · 0 citations
Sep 2026

AA-2βG attenuates nigrostriatal degeneration and related dopaminergic, redox, and inflammatory alterations in experimental parkinsonism.

Parkinson's disease (PD) is characterized by progressive nigrostriatal degeneration, dopamine depletion, and interactions among neuronal vulnerability, oxidative imbalance, and neuroinflammatory responses. AA-2βG is a chemically stable ascorbate derivative; however, its protective profile in experimental parkinsonism r...

Wei-Lei Ma, Le-Ping Yan, Jian-Hua Ding et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.